Shuai Wu

机构：Guiyang University, He Eye Hospital · ORCID：0000-0002-5620-8885

发表论文 13 篇 · 总被引 228 次 · h-index 5

代表论文

• EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition (2020 · Cancer Cell · 被引 157)
• A novel peptide-drug conjugate for glioma-targeted drug delivery (2024 · Journal of Controlled Release · 被引 26)
• Silencing expression of PHF14 in glioblastoma promotes apoptosis, mitigates proliferation and invasiveness via Wnt signal pathway (2019 · Cancer Cell International · 被引 15)
• UCP2 silencing in glioblastoma reduces cell proliferation and invasiveness by inhibiting p38 MAPK pathway (2020 · Experimental Cell Research · 被引 13)
• Histopathological auxiliary system for brain tumour (HAS-Bt) based on weakly supervised learning using a WHO CNS5-style pipeline (2023 · Journal of Neuro-Oncology · 被引 12)
• Experimental study on nuclear-targeted plasmid-based short hairpin RNA (ShRNA) to hypoxia inducible factor-1 α (PshHIF-1 α ) PshHIF-1 α nano-drug carrier system for breast cancer treatment in rats (2021 · Materials Express · 被引 3)